RBBP5 and acute myeloid leukemia: Previous reports have also demonstrated that treatment with 10 μM OICR-9429 disrupted the interaction of WDR5 with MLL1 or RBBP5 to less than 20% based on co-immunoprecipitation experiments, and treatment with 5–20 μM OICR-9429 dramatically decreased cell viability in in vitro models of AML [19].